SHANGHAI – October 30, 2026 -- Phrontline Biopharma reported partial responses in six of eight response-evaluable urothelial carcinoma patients (75%) treated with its bispecific antibody-drug conjugate (ADC) TJ101, and has dosed the first patient in a Phase Ib trial.

MADRID – October 28, 2026 -- Hengrui Pharma presented a record 64 oncology studies at the ESMO Congress 2026 in Madrid. Innovative oncology medicines generated 81.02% of the company's innovative medicine sales revenue in 2025.

Chanhassen – October 27, 2026 -- Every patient with investigator-assessed clinical deterioration in an exploratory 15-patient glioblastoma analysis showed sustained increases in lactate dehydrogenase (LDH) during treatment, Alpheus Medical, Inc. reported at the ESMO Congress 2026 in Madrid.

SHANGHAI – October 27, 2026 -- Henlius' serplulimab combined with chemotherapy delivered a median overall survival (OS) of 12.4 months versus 10.2 months for atezolizumab plus chemotherapy in the U.S. ASTRIDE study of first-line extensive-stage small cell lung cancer (ES-SCLC). The company presented the data at the European Society for Medical Oncology (ESMO) Congress 2026.

Thousand Oaks -- Amgen (NASDAQ:AMGN) will hold an investor webcast on Saturday, October 24, 2026, at 11:30 a.m. PT to discuss its oncology portfolio and selected data presented at the European Society of Medical Oncology Congress (ESMO) 2026.

Two senior executives lead Amgen's ESMO 2026 investor call

Murdo Gordon, executive vice president of Global Markets and Policy, and Jean-Charles Soria, senior vice president of oncology within Global Development, will lead the session. Other members of Amgen's management team will also take part.

Shanghai – October 18, 2026 -- Mabwell's Nectin-4-targeting antibody-drug conjugate 9MW2821 (Bulumtatug Fuvedotin, "BFv") achieved a 30.0% objective response rate in 60 efficacy-evaluable triple-negative breast cancer (TNBC) patients previously treated with a topoisomerase I (Topo I) ADC, according to Phase II data to be presented orally at the 2026 European Society for Medical Oncology (ESMO) Congress.

Indianapolis – October 18, 2026 -- Eli Lilly and Company (NYSE: LLY) will present first Phase 1 data for its investigational FRα-targeting antibody-drug conjugate sofetabart mipitecan (Sofe-M) in platinum-sensitive ovarian cancer (PSOC) at the European Society for Medical Oncology (ESMO) Congress, October 23–27 in Madrid, alongside updated data across lung, thyroid and breast cancer programs.

North Chicago – October 18, 2026 -- AbbVie will present new and updated data on seven solid tumor assets at the 2026 European Society for Medical Oncology (ESMO) Congress, October 23-27 in Madrid, the company's most expansive ESMO program to date. The data span lung, colorectal, ovarian, prostate and gastric cancers, across antibody-drug conjugates (ADCs), bispecific antibodies and combination regimens.

Cambridge, Mass. – October 15, 2026 -- The U.S. Food and Drug Administration has granted a second Fast Track Designation to Marengo Therapeutics' invikafusp alfa, extending the drug's expedited status from one tumor type to all tumor mutational burden high (TMB-H) solid tumors regardless of tissue of origin.

San Diego – – October 14, 2026 -- Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total.

About 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years.